doi:10.16139/j.1007-9610.2019.06.017

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[2] Virnig BA, Shamliyan T, Tuttle TM, et al.Diagnosis and management of ductal carcinoma in situ (DCIS)[J]. Evid Rep Technol Assess (Full Rep),2009(185):1-549.
[3] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[4] Sanders ME, Schuyler PA, Dupont WD, et al.The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up[J]. Cancer,2005,103(12):2481-2484.
[5] Collins LC, Tamimi RM, Baer HJ, et al.Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study[J]. Cancer,2005,103(9):1778-1784.
[6] Kuerer HM, Albarracin CT, Yang WT, et al.Ductal carcinoma in situ: state of the science and roadmap to advance the field[J]. J Clin Oncol,2009,27(2):279-288.
[7] Page DL, Dupont WD, Rogers LW, et al.Intraductal carcinoma of the breast: follow-up after biopsy only[J]. Cancer,1982,49(4):751-758.
[8] Dieterich M, Hartwig F, Stubert J, et al.Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival[J]. Breast,2014,23(4):346-351.
[9] Kim JY, Han W, Moon HG, et al.Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor[J]. Clin Breast Cancer,2013,13(5):385-391.
[10] Chagpar AB, McMasters KM, Sahoo S, et al. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis?[J]. Surgery,2009,146(4):561-567;discussion 567-568.
[11] Wu SG, Zhang WW, Sun JY, et al.Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a surveillance, epidemiology, and end results database analysis[J]. Cancer Manag Res,2018,10:527-534.
[12] Mylonas I, Makovitzky J, Jeschke U, et al.Expression of Her2/neu, steroid receptors (er and pr), ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (dcis) versus invasive breast cancer alone[J]. Anticancer Res,2015,25(3A):1719-1723.
[13] Wilkinson NW, Shahryarinejad A, Winston JS, et al.Concordance with breast cancer pathology reporting practice guidelines[J]. J Am Coll Surg,2003,196(1):38-43.
[14] Wong H, Lau S, Yau T, et al.Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer[J]. Br J Cancer,2010,102(9):1391-1396.
[15] Bombonati A, Sgroi DC.The molecular pathology of breast cancer progression[J]. J Pathol,2011,223(2):307-317.
[16] Casasent AK, Edgerton M, Navin NE.Genome evolution in ductal carcinoma in situ: invasion of the clones[J]. J Pathol,2017,241(2):208-218.
[17] Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al.Breast cancer precursors revisited: molecular features and progression pathways[J]. Histopathology,2010,57(2):171-192.
[18] Logullo AF, Godoy AB, Mourao-Neto M, et al.Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma[J]. Braz J Med Biol Res,2002,35(8):913-919.
[19] Lopez GS, Blanch FJ, Lopez-Gordo E, et al.Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study[J]. Int J Surg,2019,63:98-106.
[20] Lampejo OT, Barnes DM, Smith P, et al.Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component[J]. Sem Diagn Pathol,1994,11(3):215-222.
[21] Park TS, Hwang ES.Current trends in the management of ductal carcinoma in situ[J]. Oncology (Williston Park),2016,30(9):823-831.
[22] Gebreamlak EP, Niu Y.Low-grade and high-grade invasive ductal carcinomas of the breast follow divergent routes of progression[J]. Clin Oncol Cancer Res,2011,8(3):123-127.
[23] Roylance R, Gorman P, Hanby A, et al.Allelic imba-lance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways[J]. J Pathol,2010,196(1):32-36.
[24] Douglas-Jones AG, Gupta SK, Attanoos RL, et al.A cri-tical appraisal of six modern classifications of ductal carcinoma in situ of the breast(DCIS): correlation with grade of associated invasive carcinoma[J]. Histopathology,1996, 29(5):397-409.
[25] Azzopardi JG, Chepick OF, Hartman WH, et al.Epithelial Tumors[M]//WHO. Histological Typing of Breast Tumors. 2th ed. Geneva: WHO publication,1981:17-22
[26] Lester SC, Bose S, Chen YY, et al.Protocol for the examination of specimens from patients with invasive carcinoma of the breast[J]. Arch Pathol Lab Med,2009,133(10):1515-1538.
[27] Krishnan L, Jewell WR, Krishnan EC, et al.Breast cancer with extensive intraductal component: treatment with immediate interstitial boost irradiation[J]. Radiology,1992, 183(1):273-276.
[28] Touboul E, Buffat L, Belkacemi Y, et al.Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer[J]. Int J Radiat Oncol Biol Phys,1999,43(1):25-38.
[29] Cedolini C, Bertozzi S, Londero AP, et al.Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer[J]. Int J Clin Exp Pathol,2015,8(10):13304-13313.
[30] Perou CM, Sorlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J]. Nature,2000,406(6797):747-752.
[31] Sorlie T, Perou CM, Tibshirani R, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U S A,2001,98(19):10869-10874.
[32] Steinman S, Wang J, Bourne P, et al.Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast[J]. Ann Clin Lab Sci,2007,37(2):127-134.
[33] Lesurf R, Aure MR, Mork HH, et al.Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer[J]. Cell Rep,2016,16(4):1166-1179.
[34] Kim JY, Lee E, Park K, et al.Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes[J]. Oncotarget,2017,8(17):27997-28007.
[35] Miron A, Varadi M, Carrasco D, et al.PIK3CA mutations in in situ and invasive breast carcinomas[J]. J Cancer Res,2010,70(14):5674-5678.
[36] Tamimi RM, Baer HJ, Marotti J, et al.Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer[J]. Breast Cancer Res,2008,10(4):R67.
[37] Creighton CJ.The molecular profile of luminal B breast cancer[J]. Biologics,2012,6:289-297.
[38] Citri A, Yarden Y.EGF-ERBB signalling: towards the systems level[J]. Nat Rev Mol Cell Biol,2006,7(7):505-516.
[39] Elsarraj HS, Hong Y, Valdez KE, et al.Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion[J]. Breast Cancer Res,2015,17:128.
[40] Doebar SC, van den Broek EC, Koppert LB, et al. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study[J]. Breast Cancer Res Treat,2016,158(1):179-187.
[41] Lee JS, Oh M, Ko S, et al.IHC-breast cancer subtypes of invasive ductal carcinoma with predominant intraductal component as an insignificant prognostic factor: A register-based study from Korea[J]. Cancer Treat Commun,2016,7:52-57.
[42] Wong H, Lau S, Leung R, et al.Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer[J]. Med Oncol,2012,29(3):1536-1542.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 385-386.
[2]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 387-391.
[3]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395.
[4]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 396-402.
[5]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 403-405.
[6]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 411-415.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420.
[9]	YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei. Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 421-428.
[10]	PAN Ruixin, CHEN Xiaosong, SHEN Kunwei. Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 463-467.
[11]	ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472.
[12]	WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477.
[13]	LIU Miao, SHEN Yan, FU Xiaohong, HU Jiaojiao, CHEN Qingqing, YING Tao. A comparative study on breast cancer between smaller and larger diameters using conventional ultrasound and contrast-enhanced ultrasound [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 229-233.
[14]	CHEN Yuanyuan, YE Xin, TANG Yongzhe, WANG Jie, HE Qi. Prognosis of invasive micropapillary carcinoma versus invasive ductal carcinoma of the breast: a comparative analysis after propensity score matching [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 353-360.
[15]	CHEN Xiaosong, LI Shuai, WU Jiayi, HUANG Ou, CHAI Weimin, YAO Jiejie, ZHU Ying, XU Chen, CHEN Jiayi, QU Qing, FEI Xiaochun, DING Xiaoyi, LIN Lin, ZHANG Nan, FANG Qiong, HE Jianrong, ZHU Li, LI Yafen, CHEN Weiguo, SHEN Kunwei. Diagnosis, treatment and survival of breast cancer patients in single large hospital: a 10-year analysis [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 149-158.